Lynx1 Capital Management LP bought $285k of PASG
owner at Passage BIO, Inc.. 456,353 shares at an average of $0.62, traded Nov 25, 2024, filed Nov 27, 2024.
Score components
- +12Role10% owner
- +14Trade size$285k at market
- +3Relative to holdingsHoldings up 5%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.5%, 3m -23.5%, 6m -46.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-24-006799, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +259,998 | $0.56 | $147k | 8,686,953 | Nov 27, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: See footnote | +167,055 | $0.71 | $118k | 8,854,008 | Nov 27, 2024 |
| Nov 27, 2024 | POpen-market purchase Common Stockindirect: See footnote | +29,300 | $0.67 | $20k | 8,883,308 | Nov 27, 2024 |
Related signals
Other insiders at Passage BIO, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | Passage BIO, Inc. | Kathleen Borthwick CFO | $38k 2,062 shares | -28% | |
| 36Weak | Passage BIO, Inc. | William Chou PRESIDENT AND CEO | $75k 4,076 shares | -38% | |
| 35Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $224k 32,008 shares | +5% | |
| 52Moderate | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $734k 128,848 shares | +28% | |
| 24Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $197k 583,657 shares | -9% | |
| 21Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $79k 235,572 shares | -3% | |
| 19Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $50k 149,054 shares | -2% | |
| 7Weak | PASGsell Passage BIO, Inc. | Kathleen Borthwick CFO | $1,686 3,183 shares | -7% | |
| 25Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $241k 373,645 shares | +4% | |
| 23Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $138k 230,321 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.